Total Medical devices industry cross border M&A deals worth $2.7bn were announced globally in Q2 2022, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 102.3% over the previous quarter of $1.33bn and a drop of 47.2% when compared with the last four-quarter average, which stood at $5.09bn.
Comparing cross border M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $2.16bn. At the country level, the Germany topped the list in terms of deal value at $1.78bn.
In terms of volumes, Europe emerged as the top region for Medical devices industry cross border M&A deals globally, followed by North America and then Asia-Pacific.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe top country in terms of cross border M&A deals activity in Q2 2022 was the US with 11 deals, followed by Germany with nine and the UK with five.
In 2022, at the end of , cross border M&A deals worth $4.03bn were announced globally in Medical devices industry, marking a decrease of 54.5% year on year.
Cross Border M&A deals in Medical devices industry in Q2 2022: Top deals
The top five cross border M&A deals in Medical devices industry accounted for 54.5% of the overall value during Q2 2022.
The combined value of the top deals stood at $2.09bn, against the overall value of $2.7bn recorded for the quarter.
The top five Medical devices industry cross border Medical devices deals of Q2 2022 tracked by GlobalData were:
1) ResMed $1bn acquisition deal with MediFox DAN Group
2) The $541.63m acquisition of Phenox by Wallaby Medical
3) Boston Scientific $230m acquisition deal for 64% stake in M.I.Tech
4) The $177.8m acquisition of Guardant Health AMEA by Guardant Health
5) Integer $141.73m acquisition deal with Aran Biomedical
